Bioxcel Therapeutics shares fall 5.81% premarket after at-home agitation drug trial results.

Bioxcel Therapeutics, Inc. declined 5.81% in premarket trading. The company's most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer's disease in the at-home setting.